Hervé Hoppenot, Incyte CEO, is appointed on the Board of Pierre Fabre Laboratories
Castres (France), January 5th, 2024 – President and CEO of the biotechnology company Incyte since 2014, Hervé Hoppenot will bring his extensive pharmaceutical expertise to the Board of Directors of Pierre Fabre Laboratories, particularly in the field of oncology. His appointment comes at a time when Pierre Fabre is preparing to market in the US its allogeneic immunotherapy Ebvallo® which has just been awarded the prestigious Prix Galien for its therapeutic innovation. Ebvallo®’s Biologics License Application will be submitted to the Food & Drug Administration (FDA) in the second quarter of 2024.
Hervé Hoppenot, 63, a dual French American citizen, has spent most of his career in the United States. He occupied successively the positions of Vice President (VP) for the US Oncology franchise at Aventis (2000-2005), Sales Director USA and Executive VP at Novartis (2006-2010) and President of the Novartis Oncology Global franchise (2010-2014).
Hervé Hoppenot joined Incyte Corp. in 2014 as President and Chief Executive Officer, a young biotechnology company that he gradually transformed into a major player in onco-hematology. Incyte generated $3.4 billion in revenue in 2022 and invests over 40% of its revenue annually in Research & Development.
Hervé Hoppenot will also join the Strategic Committee of the Board of Directors.
Together with Pierre-Yves Revol, Chairman of the Group's controlling holding company, we are delighted to welcome Hervé Hoppenot, whose expertise and international experience will be invaluable in the further development of our oncology activities. These have more than doubled since 2019, they now account for over 40% of our Medical Care revenues and represent our first growth potential.
Roch Doliveux
Chairman of the Board
Hervé Hoppenot declared himself :
Happy and proud to join the Board of an independent company that innovates across the entire spectrum of therapy and care for patients affected by cancer, from prevention to new targeted therapies. I'm looking forward to discovering the original model of a company which is owned by a government-recognized public-interest foundation and whose humanist values resonates strongly with me.
Hervé Hoppenot
Member of the Strategic Committee of the Board of Directors
Press Contact
